Quarterly report pursuant to Section 13 or 15(d)

INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative)

v3.19.2
INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative) - USD ($)
1 Months Ended
Oct. 12, 2018
Aug. 20, 2018
Naltrexone Implant Formulation [Member] | Australia from Trinity Compound Solutions [Member]    
Aggregate purchase price, value   $ 236,000
Aggregate purchase price, Shares   10,000
Naltrexone Implant Formulation [Member] | New Zealand from Trinity Compound Solutions [Member]    
Aggregate purchase price, value   $ 236,000
Aggregate purchase price, Shares   20,000
Therakine, Ltd. [Member]    
Patent acquired $ 15,200